Ploia C.,Neuronal Death and Neuroprotection Laboratory |
Antoniou X.,Neuronal Death and Neuroprotection Laboratory |
Sclip A.,Neuronal Death and Neuroprotection Laboratory |
Grande V.,Neuronal Death and Neuroprotection Laboratory |
And 10 more authors.
Journal of Alzheimer's Disease | Year: 2011
Alzheimer's disease (AD) is a major clinical concern, and the search for new molecules to combat disease progression remains important. One of the major hallmarks in AD pathogenesis is the hyperphosphorylation of tau and subsequent formation of neurofibrillary tangles. Several kinases are involved in this process. Amongst them, c-Jun N-terminal kinases (JNKs) are activated in AD brains and are also associated with the development of amyloid plaques. This study was designed to investigate the contribution of JNK in tau hyperphosphorylation and whether it may represent a potential therapeutic target for the fight against AD. The specific inhibition of JNK by the cell permeable peptide D-JNKI-1 led to a reduction of p-tau at S202/T205 and S422, two established target sites of JNK, in rat neuronal cultures and in human fibroblasts cultures. Similarly, D-JNKI-1 reduced p-tau at S202/T205 in an in vivo model of AD (TgCRND8 mice). Our findings support the fundamental role of JNK in the regulation of tau hyperphosphorylation and subsequently in AD pathogenesis. © 2011-IOS Press and the authors. All rights reserved.